Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
Insulin Aspart Archives
Print | Email | Share | Comments (0)

Danish Drug Improves Blood Sugar Control in Type 2s


Dec 27, 2013

Danish pharmaceutical manufacturer Novo Nordisk's drug Ryzodeg, which includes two different insulin products, has been shown to significantly lower rates of hypoglycemia and has led to improved blood sugar levels for those with type 2 diabetes compared to those taking a single insulin, according to the results of a new study.

The drug is a combination of two different insulins, insulin degludec, a once-a-day basal insulin and insulin aspart, a mealtime insulin, and is injected twice daily using a pen applicator.

It was studied over a 26-week period and results were compared to those of a twice-daily single insulin.

Researchers said that those taking Ryzodeg saw lower blood sugar rates overall, along with as much as an 80 percent decrease in instances of hypoglycemia than those taking a single mealtime insulin.

"Type 2 diabetes is a progressive disease and many patients who are uncontrolled with basal insulin need to add mealtime insulin to achieve or maintain their glycemic targets over time. As Ryzodeg is a combination of two distinct insulins, a basal insulin with a long and steady action profile and a well-established mealtime insulin, it is a simple way for patients to add mealtime control with a reduced risk of overall and nocturnal confirmed, and severe hypoglycemia," said lead investigator Gregory Fulcher of Royal North Shore Hospital, Sydney, Australia.

Data was presented earlier this month at the World Diabetes Congress of the International Diabetes Federation in Copenhagen, Denmark.

Ryzodeg was approved for use to treat diabetes in Europe and the United Kingdom early last year, but in the United States, the FDA rejected Novo Nordisk's application for approval for the drug in February, and called for more study on the cardiovascular risks and safety of the drug.


Categories: Hypoglycemia, Insulin Aspart, Insulin Degludec, Ryzodeg, Type 2



You May Also Be Interested In...


Click Here To View Or Post Comments

Comments 0 comments - Dec 27, 2013

©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.